Gastrointestinal, Physiology, USMLE Step 1 - Full Vignette with Extended Explanations скачать в хорошем качестве

Gastrointestinal, Physiology, USMLE Step 1 - Full Vignette with Extended Explanations

Chapters 00:00 - Case Presentation and Question 03:27 - Correct Answer Revealed and Explanation An 81-year-old man presents with chronic loose stools, urgency, and episodes of incontinence, which worsen with stress and certain meals and improve during fasting. His history includes multiple comorbidities and previous surgeries, with normal recent testing for common etiologies. What clinical considerations and risk factors should you evaluate when selecting treatment options for persistent diarrhea in complex older adults? VIDEO INFO Category: Gastrointestinal, Physiology, USMLE Step 1 Difficulty: Expert - Expert level - For those seeking deep understanding Question Type: Contraindications Case Type: Rare Presentation Watch the video for explanation, or see the full explanation at: https://endlessmedical.academy/auth?h... QUESTION An 81-year-old retired man living with his spouse presents for evaluation of long-standing loose, nonbloody stools three to five times daily with urgency and occasional incontinence, worse with stress and restaurant meals and improved during fasting. He denies weight loss, nocturnal pain, fevers, or recent antibiotics.... OPTIONS A. Eluxadoline 75 mg orally twice daily with food in a post-cholecystectomy patient without a gallbladder B. Rifaximin 550 mg orally three times daily for 14 days for diarrhea-predominant irritable bowel syndrome C. Loperamide up to a prescription maximum of 16 mg in 24 hours as needed for watery stools when afebrile D. Alosetron 0.5 mg orally twice daily with careful monitoring for constipation and ischemic colitis Further reading: [1] Pharmacological management of irritable bowel syndrome with diarrhea (IBS-D) Authors: American Gastroenterological Association American Gastroenterological Association. Year: 2022. Type: Guideline. Educational value: Outlines indications, efficacy, and safety of IBS-D therapies. Confidence of existence and relevancy: 100% Available at: https://gastro.org/clinical-guidance/... [2] FDA Drug Safety Communication: Increased risk of serious pancreatitis with eluxadoline in patients without a gallbladder Authors: U.S. Food and Drug Administration U.S. Food and Drug Administration. Year: 2017. Type: Source. Educational value: Emphasizes safety and contraindications in IBS-D pharmacotherapy selection. Confidence of existence and relevancy: 100% Available at: https://www.fda.gov/drugs/drug-safety... Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content. --------------------------------------------------- Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations. Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification. Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases. This material can not be treated as medical advice. May contain errors. --------------------------------------------------- #USMLE #COMLEXUSA USMLE(R) is a registered trademark of the National Board of Medical Examiners (NBME). USMLE(R) is a joint program of the Federation of State Medical Boards (FSMB) and the NBME. Neither organization endorses this publication. This publication and EndlessMedical LLC have no connection or association with the USMLE(R). COMLEX-USA(R) is a registered trademark of the National Board of Osteopathic Medical Examiners (NBOME). NBOME does not endorse this publication. This publication and EndlessMedical LLC have no connection or association with COMLEX-USA(R).